Gene expression profiling in psoriatic scalp hair follicles: Clobetasol propionate shampoo 0.05% normalizes psoriasis disease markers

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 11, 2010, Pages 1304-1311

  Aubert, J ^a   Reiniche, P ^a   Fogel, P ^a   Poulin, Y ^b   Lui, H ^c   Lynde, C ^d   Shapiro, J ^d   Villemagne, H ^a   Soto, P ^a   Voegel, J J ^a  

^a Galderma R and D   (France)

^b Centre de Recherche Dermatologique du Quebec Métropolitain   (France)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Lynderm Clinical Research   (Canada)

Author keywords

Gene expression profiling; Hair follicle; Inflammation; Scalp psoriasis

Indexed keywords

BETA DEFENSIN 4; CALGRANULIN; CALGRANULIN B; CLOBETASOL PROPIONATE; CLOBEX; HEPARANASE; INTERFERON; INTERLEUKIN 8; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PSORIASIN; RNA; SHAMPOO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; GENE CONTROL; GENE EXPRESSION; HAIR FOLLICLE; HAIR GROWTH; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MODULATION; OPEN STUDY; PRIORITY JOURNAL; PSORIASIS; RNA EXTRACTION; SCALP HAIR; TRANSCRIPTOMICS; UPREGULATION;

EID: 78649723111     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03637.x     Document Type: Article

References (54)

1. Van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol 2001; 2: 159-165.
2. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-873.
3. Jarratt M, Breneman D, Gottlieb AB et al. Clobetasol propionate shampoo 0. 05%: A new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004; 3: 367-373.
4. Andres P, Poncet M, Sidou F, Soto P. Short-term safety assessment of clobetasol propionate 0. 05% shampoo: Hypothalamic-pituitary-adrenal axis suppression, atrophogenicity and ocular safety in subjects with scalp psoriasis. J Drugs Dermatol 2006; 5: 328-332.
5. Reygagne P, Mrowietz U, Decroix J et al. Clobetasol propionate shampoo 0. 05% and calcipotriol solution 0. 005%: A randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatol Treat 2005; 16: 31-36.
6. Griffiths CEM, Finlay AY, Fleming CJ et al. A randomized, investigatormasked clinical evaluation of the efficacy and safety of clobetasol propionate shampoo 0. 05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatol Treat 2006; 17: 90-95.
7. Kunz M, Ibrahim SM, Koczan D et al. DNA microarray technology and its applications in dermatology. Exp Dermatol 2004; 13: 593-606.
8. Kunz M. DNA microarray technology in dermatology. Semin Cutan Med Surg 2008; 27: 16-24.
9. Bowcock AM, Shannon W, Du F et al. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet 2001; 10: 1793-1805.
10. Oestreicher JL, Walters IB, Kikuchi T et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 2001; 1: 272-287.
11. Wong R, Tran V, Morhenn V et al. Use of RT-PCR and DNA microarrays to characterize RNA recovered by non-invasive tape harvesting of normal and inflamed skin. J Invest Dermatol 2004; 123: 159-167.
12. Benson NR, Papenfuss J, Wong R et al. An analysis of select pathogenic messages in lesional and non-lesional psoriatic skin using non-invasive tape harvesting. J Invest Dermatol 2006; 126: 2234-2241.
13. Hards BD, Zhao X, Zhang J et al. Assignment of psoriasin to human chromosomal band 1q21: Co-ordinate overexpression of clustered genes in psoriasis. J Invest Dermatol 1996; 106: 753-758.
14. Schroder JM, Harder J. Human beta-defensin-2. Int J Biochem Cell Biol 1999; 31: 645-651.
15. Koczan D, Guthke R, Thiesen HJ et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol 2005; 15: 251-257.
16. Reischl J, Schwenke S, Beekman JM et al. Increased Expression of Wnt5a in Psoriatic Plaques. J Invest Dermatol 2007; 127: 163-169.
17. Zhou X, Krueger JG, Kao MC et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100- element oligonucleotide array. Physiol Genomics 2003; 13: 69-78.
18. Quekenborn-Trinquet V, Fogel P, Aldana-Jammayrac O et al. Gene expression profiles in psoriasis: Analysis of impact of body site location and clinical severity. Br J Dermatol 2005; 152: 489-504.
19. Bonifati C, Carducci M, Cordiali P et al. Correlated increase of tumor necrosis factor-a, interleukin-6 and granulocyte monocytecolony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationship with disease severity. Clin Exp Dermatol 1994; 19: 383-387.
20. Alkemade H, de Jongh G, Arnold P et al. Levels of skin-derived antileukoproteinase (SKALP)/elafin in serum correlate with disease activity during treatment of severe psoriasis with cyclosporine A. J Incest dermatol 1995; 104: 189-193.
21. De pita O, Frezzolini A, Cianetti A et al. Squamous cell carinomarelated antigen (SCCr-Ag), sICAM-1 and beta-2microglobulin are useful markers of disease activity in psoriasis. Acta Derm Venereol (Stockh) 1999; 79: 132-135.
22. Szepietowski J, Wasik F, Bielicka E et al. Soluble E-selectin serum levels correlate with disease activity in psoriatic patients. Clin Exp Dermatol 1999; 24: 33-36.
23. Inaoki M, Sato S, Shimada Y et al. Decreased expression levels of L-selectin on subsets of leucocytes and increased serum L-selectin in severe psoriasis. Clin Exp Immunol 2000; 122: 484-492.
24. Haider AS, Cohen J, Fei J et al. Insights into gene modulation by therapeutic TNF and IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF-regulated genes linked to psoriasis transcriptome. J Invest Dermatol 2008; 128: 655-666.
25. Rappersberger K, Komar M, Ebelin ME et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002; 119: 876-887.
26. Bardazzi F, Fanti PA, Orlandi C et al. Psoriatic scarring alopecia: Observations in four patients. Int J Dermatol 1999; 38: 765-768.
27. Wilson CL, Dean D, Lane EB et al. Keratinocyte differentiation in psoriatic scalp: Morphology and expression of epithelial keratins. Br J Dermatol 1994; 131: 191-200.
28. Katsuoka K, Schell H, Deinlein E, Hornstein OP. Cell kinetics of the human anagen hair follicle. Flow cytometric studies in healthy and psoriatic subjects. Dermatologica 1987; 174: 105-109.
29. Sawan S, Descamps V. Scalp psoriasis: A paradigm of "switch-on" mechanism to anagen hair growth? Arch Dermatol 2008; 144: 1064-1066.
30. Poulin Y, Papp K, Bissonnette R et al. Clobetasol propionate shampoo 0. 05% is efficacious and safe for long-term control of scalp psoriasis. Cutis 2010; 85: 43-50.
31. Wulff-Woesten A, Ohlendorf D, Henz BM, Haas N. Dithranol is an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp. Skin Pharmacol Physiol 2004; 17: 91-97.
32. Chiu ST, Hsieh FJ, Chen SW et al. Clinicopathologic correlation of up-regulated genes identified using cDNA microarray and real-time reverse transcription-PCR in human colorectal cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 437-443.
33. Lü B, Xu J, Chen J et al. TaqMan low density array is roughly right for gene expression quantification in colorectal cancer. Clin Chim Acta 2008; 389: 146-151.
34. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955; 50: 1096-1121.
35. Fleige S, Pfaffl MW. RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med 2006; 27: 126-139.
36. Goulter AB, Harmer DW, Clark KL. Evaluation of low density array technology for quantitative parallel measurement of multiple genes in human tissue. BMC Genomics 2006; 7: 34.
37. Wong R, Tran V, Morhenn V et al. Use of RT-PCR and DNA microarrays to characterize RNA recovered by non-invasive tape harvesting of normal and inflamed skin. J Invest Dermatol 2004; 123: 156-167.
38. Wong R, Tran V, Talwalker S, Benson NR. Analysis of RNA recovery and gene expression in the epidermis using non-invasive tape stripping. J Dermatol Sci 2006; 44: 81-92.
39. Pietrzak AT, Zalewska A, Chodorowska G et al. Cytokines and anticytokines in psoriasis. Clin Chim Acta 2008; 394: 7-21.
40. Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N. isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993; 268: 10425-10432.
41. Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin: A novel mediator of innate immunity. J Leukoc Biol 2008; 83: 804-816.
42. McKenzie EA. Heparanase: A target for drug discovery in cancer and inflammation. Br J Pharmacol 2007; 151: 1-14.
43. Yamasaki K, Gallo RL. Antimicrobial peptides in human disease. Eur J Dermatol 2008; 18: 11-21.
44. Zheng Y, Niyonsaba F, Ushio H et al. Microbicidal protein psoriasin is a multifunctional modulator of neutrophil activation. Immunology 2008; 124: 357-367.
45. Gebhardt C, Németh J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006; 72: 1622-1631.
46. Donato R. RAGE: A single receptor for several ligands and different cellular responses: The case of certain S100 proteins. Curr Mol Med 2007; 7: 711-724.
47. Suomela S, Cao L, Bowcock A, Saarialho-Kere U. Interferon alphainducible protein 27 (IFI27) is upregulated in psoriatic skin and certain epithelial cancers. J Invest Dermatol 2004; 122: 717-721.
48. Michalik L, Wahli W. Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim Biophys Acta 2007; 1771: 991-998.
49. Romanowska M, al Yacoub N, Seidel H et al. PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol 2008; 128: 110-124.
50. Morand EF. Effects of glucocorticoids on inflammation and arthritis. Curr Opin Rheumatol 2007; 19: 302-307.
51. Bowcock AM, Krueger JG. Getting under the skin: The immunogenetics of psoriasis. Nat Rev Immunol 2005; 5: 699-711.
52. Food and Drug Administration. Innovation/stagnation: Challenge and opportunity on the critical path to new medical products [WWW document] 2004. URL http://www. fda. gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/ucm078933. pdf (last accessed: 2 March 2010).
53. Commission of the European Communities. Proposal for a council regulation setting up the innovative medicines initiative joint undertaking [WWW document] 2007. URL http://eur-lex. europa. eu/LexUriServ/site/en/com/2007/com2007- 0241en01. pdf (last accessed: 2 March 2010).
54. Food and Drug Administration. Guidance for industry, investigators, and reviewers: Exploratory IND studies [WWW document] 2006. URL http://eur-lex. europa. eu/LexUriServ/site/en/com/2007/com2007-0241 en01. pdf (last accessed: 2 March 2010)